the American Society of Addiction Medi-
cine, the American Academy of Addiction 
Psychiatry, the American Medical Associa-
tion, the American Osteopathic Associa-
tion, the American Nurses Credentialing 
Center, the American Psychiatric Associa-
tion, the American Association of Nurse 
Practitioners, the American Academy of 
Physician Assistants, or any other organi-
zation that the Secretary determines is ap-
propriate for purposes of this subclause. 
‘‘(bb) Has such other training or ex-
perience as the Secretary determines will 
demonstrate the ability of the nurse practi-
tioner or physician assistant to treat and 
manage opiate-dependent patients. 
‘‘(III) The nurse practitioner or physician 
assistant is supervised by or works in collabora-
tion with a qualifying physician, if the nurse 
practitioner or physician assistant is required 
by State law to prescribe medications for the 
treatment of opioid use disorder in collaboration 
with or under the supervision of a physician.
The Secretary may review and update the require-
ments for being a qualifying other practitioner under 
this clause.’’; and 
(4) in subparagraph (H)— 
(A) in clause (i), by inserting after sub-
clause (II) the following: 
‘‘(III) Such other elements of the requirements 
under this paragraph as the Secretary determines 
necessary for purposes of implementing such re-
quirements.’’; and 
(B) by amending clause (ii) to read as fol-
lows: 
‘‘(ii) Not later than 1 year after the date of enact-
ment of the Opioid Use Disorder Treatment Expansion 
and Modernization Act, the Secretary shall update the 
treatment improvement protocol containing best practice 
guidelines for the treatment of opioid-dependent patients 
in office-based settings. The Secretary shall update such 
protocol in consultation with experts in opioid use disorder 
research and treatment.’’. 
(b) RECOMMENDATION OF REVOCATION OR SUSPEN-
SION OF REGISTRATION IN CASE OF SUBSTANTIAL NON-
COMPLIANCE.—The Secretary of Health and Human 
Services may recommend to the Attorney General that the 
registration of a practitioner be revoked or suspended if
the Secretary determines, according to such criteria as the 
Secretary establishes by regulation, that a practitioner 
who is registered under section 303(g)(2) of the Controlled 
Substances Act (21 U.S.C. 823(g)(2)) is not in substantial 
compliance with the requirements of such section, as 
amended by this Act. 
(c) OPIOID DEFINED.—Section 102(18) of the Con-
trolled Substances Act (21 U.S.C. 802(18)) is amended 
by inserting ‘‘or ‘opioid’ ’’ after ‘‘The term ‘opiate’ ’’. 
(d) REPORTS TO CONGRESS.— 
(1) IN GENERAL.—Not later than 2 years after 
the date of enactment of this Act and not less than 
over every 5 years thereafter, the Secretary of 
Health and Human Services, in consultation with 
the Drug Enforcement Administration and experts 
in opioid use disorder research and treatment, 
shall— 
(A) perform a thorough review of the pro-
vision of opioid use disorder treatment services 
in the United States, including services pro-
vided in opioid treatment programs and other 
specialty and nonspecialty settings; and 
(B) submit a report to the Congress on the 
findings and conclusions of such review.
(2) CONTENTS.—Each report under paragraph 
(1) shall include an assessment of— 
(A) compliance with the requirements of 
section 303(g)(2) of the Controlled Substances 
Act (21 U.S.C. 823(g)(2)), as amended by this 
Act; 
(B) the measures taken by the Secretary of 
Health and Human Services to ensure such 
compliance; 
(C) whether there is further need to in-
crease or decrease the number of patients a 
waivered practitioner is permitted to treat, as 
provided for by the amendment made by sub-
section (a)(1); 
(D) the extent to which, and proportions 
with which, the full range of Food and Drug 
Administration-approved treatments for opioid 
use disorder are used in routine health care set-
tings and specialty substance use disorder treat-
ment settings; 
(E) access to, and use of, counseling and 
recovery support services, including the percent-
age of patients receiving such services;
(F) changes in State or local policies and 
legislation relating to opioid use disorder treat-
ment; 
(G) the use of prescription drug moni-
toring programs by practitioners who are per-
mitted to dispense narcotic drugs to individuals 
pursuant to a waiver under section 303(g)(2) of 
the Controlled Substances Act (21 U.S.C. 
823(g)(2)); 
(H) the findings resulting from inspections 
by the Drug Enforcement Administration of 
practitioners described in subparagraph (G); 
and 
(I) the effectiveness of cross-agency col-
laboration between Department of Health and 
Human Services and the Drug Enforcement 
Administration for expanding effective opioid 
use disorder treatment. 
SEC. 4. SENSE OF CONGRESS. 
It is the Sense of Congress that, with respect to the 
total number of patients that a qualifying physician (as 
defined in subparagraph (G)(iii) of section 303(g)(2) of 
the Controlled Substances Act (21 U.S.C. 823(g)(2)) can 
treat at any one time pursuant to such section, the Sec-
retary of Health and Human Services should consider